Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 3/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PRF1 | P14222 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956508 | 1.00 | CA2 (0.54) | CA2CYP2A6FLT3PDGFRBPDGFRA | |
| SCHEMBL92643 | 0.86 | AXL (0.59) | CA2CYP2A6FLT3PDGFRBPDGFRA | |
| SCHEMBL29953506 | 0.86 | AXL (0.59) | CA2CYP2A6FLT3PDGFRBPDGFRA | |
| SCHEMBL20853005 | 0.83 | CA2 (0.50) | CA2CYP2A6FLT3PDGFRBPDGFRA | |
| SCHEMBL12143604 | 0.80 | CYP2A6 (0.46) | CA2CYP2A6FLT3MAPTKMT2A | |
| SCHEMBL29956595 | 0.79 | KDM4E (0.51) | CA2FLT3PDGFRBPDGFRAALDH1A1 | |
| SCHEMBL1039269 | 0.79 | KDM4E (0.51) | CA2FLT3PDGFRBPDGFRAALDH1A1 | |
| SCHEMBL27374831 | 0.79 | CYP2A6 (0.49) | CYP2A6HPGDMAOB | |
| SCHEMBL29466343 | 0.77 | CYP2A6 (0.58) | CYP2A6FLT3ALDH1A1KDM4EMAPT | |
| SCHEMBL5361224 | 0.77 | CYP2A6 (0.58) | CYP2A6FLT3ALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302842-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATMENT OF CANCERS | Jubilant Epipad LLC | 2025-10-02 | — | — | US | disclosed |
| US-12357639-B2 | Heterocyclic compounds as pad inhibitors | Jubilant Epipad LLC (US) | 2025-07-15 | — | — | US | disclosed |
| CN-119775261-A | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-115427404-B | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240156831-A1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC | 2024-05-16 | — | — | US | disclosed |
| EP-3684767-B1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| EP-3684767-B1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| US-11833156-B2 | Heterocyclic compounds as pad inhibitors | Jubilant Epipad LLC (US) | 2023-12-05 | — | — | US | disclosed |
| US-11833156-B2 | Heterocyclic compounds as pad inhibitors | Jubilant Epipad LLC (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230150980-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-05-18 | — | — | US | disclosed |
| CN-105418506-A | Acetobenzylamide piperazine derivative and application thereof as cranial nerve protective agent | SHANGHAI INST PHARMACEUTICAL IND | 2016-03-23 | — | — | CN | disclosed |
| US-20150191439-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-09 | — | — | US | disclosed |
| CN-102432522-B | Method for preparing substituted 2-indolinone compound | UNIV PLA 2ND MILITARY MEDICAL | 2014-04-02 | — | — | CN | disclosed |
| WO-2013086131-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-06-13 | — | — | WO | disclosed |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20090286863-A1 | SULFAMATOBENZOTHIOPHENE DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2009-11-19 | — | — | US | disclosed |
| US-20080171772-A1 | e.g. Methyl 1-Benzyl-6-methoxy-1H-indole-2-carboxylate; glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, wound healing, platelet aggregation and thrombosis | ALLERGAN, INC. | 2008-07-17 | — | — | US | disclosed |
| US-7094798-B1 | Inhibitors of checkpoint kinases (Wee1 and Chk1) | PFIZER INC (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1501831-A1 | INHIBITORS OF CHECKPOINT KINASES (WEE1 AND CHK1) | WARNER-LAMBERT COMPANY LLC (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003091255-A1 | INHIBITORS OF CHECKPOINT KINASES (WEE1 AND CHK1) | WARNER-LAMBERT COMPANY LLC (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150980-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | COL1A1, COL2A1, COL14A1 | CA2 4443/4885CYP2A6 3412/4885FLT3 4754/4885 |
| US-11833156-B2 | Heterocyclic compounds as pad inhibitors | PADI4, PADI2, PADI1 | CA2 1299/4885CYP2A6 935/4885FLT3 398/4885 |
| US-20250302842-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATMENT OF CANCERS | NES, VHL, ETV6 | CA2 2367/4885CYP2A6 2661/4885FLT3 13/4885 |
| US-20240156831-A1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | PADI4, PADI2, PADI1 | CA2 3323/4885CYP2A6 1259/4885FLT3 59/4885 |
| US-20080171772-A1 | e.g. Methyl 1-Benzyl-6-methoxy-1H-indole-2-carboxylate; glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, wound healing, platelet aggregation and thrombosis | PTGIR, S1PR1, TBXA2R | CA2 2089/4885CYP2A6 554/4885FLT3 1924/4885 |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | CA2 1991/4885CYP2A6 2192/4885FLT3 4298/4885 |
| US-20150191439-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | HAVCR2, HDLBP, HSP90B1 | CA2 1856/4885CYP2A6 2137/4885FLT3 1350/4885 |
| US-12357639-B2 | Heterocyclic compounds as pad inhibitors | PADI4, PADI2, PADI1 | CA2 3323/4885CYP2A6 1259/4885FLT3 59/4885 |
| US-20090286863-A1 | SULFAMATOBENZOTHIOPHENE DERIVATIVES | SULT1A1, SULT1E1, SULT2A1 | CA2 1619/4885CYP2A6 94/4885FLT3 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.